1-2 of 2
Kumiko Yanase
Close
Sort by
Journal Articles

Ponatinib Safety and Efficacy in Japanese Patients with Philadelphia Positive Leukemia: Update of a Phase 1/2 Study

Taiichi Kyo, Arinobu Tojo, MD PhD, Kazuhito Yamamoto, Naoto Takahashi, Hirohisa Nakamae, Yukio Kobayashi, Tetsuzo Tauchi, Shinichiro Okamoto, Koichi Miyamura, Hiromi Iwasaki, MD PhD, Kiyohiko Hatake, MD PhD, Itaru Matsumura, Noriko Usui, Kumiko Yanase, Simin Hu, Tomoki Naoe, Kazuma Ohyashiki
Journal: Blood
Blood (2014) 124 (21): 5541.
https://doi.org/10.1182/blood.V124.21.5541.5541
Published: 2014
Journal Articles

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Philipp D. Le Coutre, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. Dipersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Kumiko Yanase, MD, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, DM, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 1496.
https://doi.org/10.1182/blood.V122.21.1496.1496
Published: 2013